The Net Margin of Vanda Pharmaceuticals Inc (VNDA) is
-102.02%.
Net Margin measures the percentage of net income derived from total revenue after all expenses. It signals how much actual profit a company retains from its sales.
| Date |
Value |
| 2025-12-31 |
-102.02%
|
| 2024-12-31 |
-9.51%
|
| 2023-12-31 |
1.30%
|
| 2022-12-31 |
2.48%
|
| 2021-12-31 |
12.36%
|
| 2020-12-31 |
9.39%
|
| 2019-12-31 |
50.88%
|
| 2018-12-31 |
13.05%
|
| 2017-12-31 |
-9.45%
|
| 2016-12-31 |
-12.33%
|
| Ticker |
Name |
Value |
|
ARCT
|
Arcturus Therapeutics Holdings Inc
|
-80.19%
|
|
INBX
|
Inhibrx Biosciences Inc
|
-10773.46%
|
|
MRUS
|
Merus NV
|
-595.02%
|
|
MTEM
|
Molecular Templates Inc
|
-14.18%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
31.41%
|
|
950220.KQ
|
Neoimmunetech Inc
|
-33533.01%
|
|
AMGN
|
Amgen Inc
|
20.98%
|
|
GILD
|
Gilead Sciences, Inc.
|
28.90%
|
|
IDYA
|
IDEAYA Biosciences, Inc.
|
-51.99%
|
|
KDNY
|
Chinook Therapeutics Inc
|
-3065.68%
|
|
ABBV
|
AbbVie Inc.
|
6.91%
|
|
ACIU
|
AC Immune AG
|
-1971.65%
|
|
CLVS
|
Clovis Oncology Inc
|
-177.82%
|
|
DTIL
|
Precision Biosciences, Inc
|
-133.45%
|
|
VYGR
|
Voyager Therapeutics, Inc.
|
-296.53%
|
|
AFMD
|
Affimed NV
|
-1280.22%
|
|
CTMX
|
CytomX Therapeutics, Inc.
|
-22.79%
|
|
GTHX
|
G1 Therapeutics Inc
|
-58.13%
|
|
KPTI
|
Karyopharm Therapeutics Inc.
|
-134.21%
|
|
JNCE
|
Jounce Therapeutics Inc
|
-62.10%
|
|
XBIT
|
XBiotech Inc
|
-820.45%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
-3733.25%
|
|
ANAB
|
AnaptysBio, Inc.
|
246.96%
|
|
CNTG
|
Centogene NV
|
-73.21%
|
|
DVAX
|
Dynavax Technologies Corp
|
9.85%
|
|
FMTX
|
Forma Therapeutics Holdings Inc
|
-34.59%
|
|
AGEN
|
Agenus Inc
|
0.10%
|
|
EPZM
|
Epizyme Inc
|
-670.96%
|
|
IMGN
|
ImmunoGen Inc
|
-204.87%
|
|
KALV
|
KalVista Pharmaceuticals, Inc.
|
-223.16%
|
|
SGTX
|
Sigilon Therapeutics Inc
|
-336.53%
|
|
SURF
|
Surface Oncology Inc
|
-211.95%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
32.94%
|
|
950200.KQ
|
Psomagen Inc
|
-5.04%
|
|
MRNA
|
Moderna, Inc.
|
-145.16%
|
|
RGNX
|
REGENXBIO Inc.
|
-113.75%
|
|
RIGL
|
Rigel Pharmaceuticals, Inc.
|
124.72%
|